HomeMarket NewsRayzeBio Receives Buy Rating from William Blair, Poised to Lead in Radiopharmaceuticals

RayzeBio Receives Buy Rating from William Blair, Poised to Lead in Radiopharmaceuticals

Actionable Trade Ideas

always free

Bull market, Financial and business concept


RayzeBio, a leading company in the field of radiopharmaceuticals, has recently received a buy rating from William Blair.

In their analysis, William Blair highlights RayzeBio’s potential to become a leader in the radiopharmaceutical industry. The investment bank specifically mentions RYZ101, the company’s lead therapy candidate currently in Phase 3 testing for neuroendocrine tumors. With a β€œhigh chance of success,” RYZ101 also has the potential for application in treating small-cell lung cancer, which could further enhance the success of RayzeBio’s RYZ101 franchise. Additionally, William Blair notes that RYZ101 could become the first approved actinium-225-based radiopharmaceutical.

William Blair also emphasizes the strategic advantage of RayzeBio’s in-house production capabilities. While maintaining external supply agreements, the company’s ability to produce and radiolabel actinium-225 internally adds redundancy and ensures a consistent source of radiopharmaceuticals for both clinical and commercial purposes. This distinguishing feature sets RayzeBio apart from other clinical-stage radiopharmaceutical companies.

Swing Trading Ideas and Market Commentary

Need some new swing ideas? Get free weekly swing ideas and market commentary from Jonathan Bernstein here: Swing Trading.

Explore More

Weekly In-Depth Market Analysis and Actionable Trade Ideas

Get institutional-level analysis and trade ideas to take your trading to the next level, sign up for free and become apart of the community.